Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Healthcare
Create a narrative
SI-BONE Community
NasdaqGM:SIBN Community
3
Narratives
written by author
0
Comments
on narratives written by author
2
Fair Values set
on narratives written by author
Community Investing Ideas
SI-BONE
Popular
Undervalued
Overvalued
SI-BONE
AN
AnalystLowTarget
Consensus Narrative from 9 Analysts
Rising US Reimbursement Risk Will Curb Opportunities Yet Allow Recovery
Key Takeaways Expanding into new procedures and markets holds promise, but execution risks and payer preferences for non-surgical solutions may curb sustainable growth. Dependence on a limited product line raises vulnerability to competitor disruption, while sustained investment needs could restrict profitability improvements.
View narrative
US$20.00
FV
22.3% undervalued
intrinsic discount
14.52%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
SI-BONE
AN
AnalystHighTarget
Consensus Narrative from 9 Analysts
Aging And Advancing Healthcare Will Expand Minimally Invasive Markets
Key Takeaways Accelerated physician adoption, international expansion, and strong innovation pipeline position SI-BONE for much faster revenue and margin growth than current expectations. Aging demographics, superior training programs, and operational efficiencies will drive sustained demand, increased procedure volumes, and expanding market share.
View narrative
US$31.60
FV
50.8% undervalued
intrinsic discount
15.90%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
SI-BONE
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
Expanding Minimally Invasive Procedures Will Open US And European Markets
Key Takeaways Accelerating physician adoption and regulatory wins are expanding procedure access, driving robust growth across both domestic and international markets. Diversifying the product lineup and gaining positive reimbursement trends are enhancing profitability prospects and supporting long-term margin expansion.
View narrative
US$25.00
FV
37.8% undervalued
intrinsic discount
14.80%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
5 days ago
author updated this narrative
Your Valuation for
SIBN
SIBN
SI-BONE
Your Fair Value
US$
Current Price
US$15.54
23.7% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-66m
360m
2015
2018
2021
2024
2025
2027
2030
Revenue US$359.8m
Earnings US$51.6m
Advanced
Set Fair Value